Tempest CAR-T Manufacturing Milestone Paves Way for Pivotal Trial

Event summary

  • Tempest Therapeutics received lentiviral vector delivery from Cincinnati Children’s Applied Gene and Cell Therapy Center, a key component for TPST-2003 manufacturing.
  • The milestone supports the initiation of a potentially registrational study for TPST-2003 in rrMM by Q4 2026.
  • Interim data from the REDEEM-1 trial showed 100% complete response in six evaluable patients, with a median PFS of 23.1 months.
  • Tempest has accumulated data from 36 patients, representing one of the largest datasets for a dual-targeting CD19/BCMA CAR-T therapy.

The big picture

Tempest's progress with TPST-2003 highlights the continued innovation in CAR-T therapies, particularly the move towards dual-targeting approaches to overcome resistance and improve efficacy in relapsed/refractory multiple myeloma. The reliance on contract manufacturing organizations (CMOs) like AGCTC underscores the capital-intensive nature of cell therapy development and the importance of these partnerships for clinical advancement. The 100% complete response rate, while promising, needs to be validated in a larger, pivotal trial to confirm the therapy's clinical benefit and commercial viability.

What we're watching

Clinical Efficacy
The upcoming presentation of REDEEM-1 and IIT data will be critical in validating the observed complete response rates and assessing the therapy’s long-term durability, particularly in patients with extramedullary disease.
Manufacturing Scale
The ability of Cincinnati Children’s AGCTC to consistently manufacture TPST-2003 lentiviral vector at the scale required for a pivotal trial will be a key determinant of the trial’s timeline and success.
Regulatory Pathway
The FDA’s assessment of the TPST-2003 data and the proposed trial design will influence the likelihood of accelerated approval and the overall commercial potential of the therapy.

Related topics

Biotechnology